January 15, 2021 – Thermo Fisher Scientific Inc. (Waltham, MA) and Groupe Novasep SAS announced that Thermo Fisher has completed the acquisition of Henogen S.A., Novasep’s viral vector manufacturing business in Belgium for approximately $878 million in cash.
Novasep’s viral vector manufacturing business provides contract manufacturing services for vaccines and therapies to biotechnology companies and large biopharma customers.
Novasep’s viral vector business has two locations in Seneffe and Gosselies, Belgium, offering more than 7,000 square meters of state-of-the-art clinical and commercial manufacturing capacity. The business has approximately 400 employees with substantial operational and technical expertise in a broad range of viral vector classes and estimated 2020 revenue of approximately $95 million.
The business will be part of the Pharma Services business within the Laboratory Products and Services Segment of Thermo Fisher Scientific.